McKesson Corporation $MCK Shares Purchased by Calamos Wealth Management LLC

Calamos Wealth Management LLC raised its position in shares of McKesson Corporation (NYSE:MCK) by 27.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,835 shares of the company’s stock after acquiring an additional 1,489 shares during the period. Calamos Wealth Management LLC’s holdings in McKesson were worth $5,836,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Secure Asset Management LLC boosted its stake in shares of McKesson by 484.8% in the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock valued at $1,604,000 after purchasing an additional 1,760 shares in the last quarter. Royal London Asset Management Ltd. increased its position in McKesson by 1.1% in the 2nd quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock valued at $84,809,000 after acquiring an additional 1,216 shares in the last quarter. BayBridge Capital Group LLC raised its stake in shares of McKesson by 268.0% in the second quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock worth $1,468,000 after acquiring an additional 1,415 shares during the last quarter. Benchmark Investment Advisors LLC acquired a new position in shares of McKesson during the second quarter worth approximately $441,000. Finally, Summit Global Investments bought a new stake in shares of McKesson during the second quarter valued at approximately $1,159,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Performance

MCK traded down $11.21 during trading on Friday, reaching $1,060.79. 812,129 shares of the company’s stock were exchanged, compared to its average volume of 691,239. The company’s fifty day moving average price is $938.13 and its 200-day moving average price is $868.12. The firm has a market capitalization of $123.68 billion, a PE ratio of 27.28, a P/E/G ratio of 1.99 and a beta of 0.27. McKesson Corporation has a fifty-two week low of $723.68 and a fifty-two week high of $1,121.50.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. During the same quarter in the prior year, the business posted $9.86 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Research analysts forecast that McKesson Corporation will post 45.26 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be given a $0.94 dividend. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 9.67%.

Insider Activity at McKesson

In other McKesson news, CAO B Jr sold 111 shares of McKesson stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 650 shares of McKesson stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total value of $716,924.00. Following the transaction, the executive vice president owned 4,414 shares in the company, valued at $4,868,465.44. This trade represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,462 shares of company stock worth $2,511,106 in the last quarter. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on MCK. TD Cowen upped their price objective on McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company boosted their target price on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Bank of America raised their price target on McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,026.18.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.